<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250212195220&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250212195220&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 13 Feb 2025 00:52:21 +0000</lastbuilddate>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Patient Enrollment for Cardiovascular Clinical Trials in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5537. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937520</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5537>10.1001/jamacardio.2024.5537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937520</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Adeena Jamil</dc:creator>
<dc:creator>Muteia Shakoor</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>J Michael DiMaio</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Patient Enrollment for Cardiovascular Clinical Trials in the United States</dc:title>
<dc:identifier>pmid:39937520</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5537</dc:identifier>
</item>
<item>
<title>Intensive Blood Pressure Control in Older Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5447. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937510</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5447>10.1001/jamacardio.2024.5447</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937510</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yuxian Huang</dc:creator>
<dc:creator>Xiangmin Tan</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Intensive Blood Pressure Control in Older Adults</dc:title>
<dc:identifier>pmid:39937510</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5447</dc:identifier>
</item>
<item>
<title>Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: In the OCEAN(a)-DOSE multicenter randomized clinical trial, olpasiran led to a significant and sustained reduction in OxPL-apoB but no significant effects on hs-CRP or hs-IL-6.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5433. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Lipoprotein(a) (Lp[a]) is thought to be the major carrier of oxidized phospholipids (OxPL). OxPL are believed to be a potent driver of inflammation and atherosclerosis. Olpasiran, a small interfering RNA, blocks Lp(a) production by inducing degradation of apolipoprotein(a) messenger RNA. Olpasiran's effects on OxPL and systemic markers of inflammation are not well described.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the effects of olpasiran on OxPL, high-sensitivity interleukin 6 (hs-IL-6), and hs-C-reactive protein (hs-CRP) in the OCEAN(a)-DOSE randomized clinical trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: OCEAN(a)-DOSE was an international, multicenter, placebo-controlled, phase 2, dose-finding randomized clinical trial conducted between July 2020 and November 2022. A total of 281 patients with atherosclerotic cardiovascular disease and Lp(a) levels greater than 150 nmol/L were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Participants were randomized to receive 1 of 4 active subcutaneous doses of olpasiran vs placebo: (1) 10 mg, administered every 12 weeks (Q12W); (2) 75 mg, Q12W; (3) 225 mg, Q12W; or (4) 225 mg, administered every 24 weeks (Q24W). OxPL on apolipoprotein B (OxPL-apoB), hs-CRP, and hs-IL-6 were assessed at baseline, week 36, and week 48 in 272 patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was placebo-adjusted change in OxPL-apoB from baseline to week 36.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 272 participants, median (IQR) age was 62 years (56-69), and 86 participants (31.6%) were female. Baseline median (IQR) Lp(a) concentration was 260.3 nmol/L (198.1-352.4) and median (IQR) OxPL-apoB concentration was 26.5 nmol/L (19.7-33.9). The placebo-adjusted mean percentage change in OxPL-apoB from baseline to week 36 was -51.6% (95% CI, -64.9% to -38.2%) for the 10-mg Q12W dose, -89.7% (95% CI, -103.0% to -76.4%) for the 75-mg Q12W dose, -92.3% (95% CI, -105.6% to -78.9%) for the 225-mg Q12W dose, and -93.7% (95% CI, -107.1% to -80.3%) for the Q24W dose (P &lt; .001 for all). These effects were maintained to week 48 (-50.8%, -100.2%, -104.7%, and -85.8%, respectively; P &lt; .001 for all). There was a strong correlation between percentage reduction in Lp(a) and OxPL-apoB for patients treated with olpasiran (r = 0.79; P &lt; .001). Olpasiran did not significantly impact hs-CRP or hs-IL-6 compared with placebo to weeks 36 or 48 (P >; .05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: In the OCEAN(a)-DOSE multicenter randomized clinical trial, olpasiran led to a significant and sustained reduction in OxPL-apoB but no significant effects on hs-CRP or hs-IL-6.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937508</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5433>10.1001/jamacardio.2024.5433</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937508</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Seth J Baum</dc:creator>
<dc:creator>Elmer Stout</dc:creator>
<dc:creator>Norman E Lepor</dc:creator>
<dc:creator>Jeong-Gun Park</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Beat Knusel</dc:creator>
<dc:creator>Jingying Wang</dc:creator>
<dc:creator>Tomaz Wilmanski</dc:creator>
<dc:creator>Huei Wang</dc:creator>
<dc:creator>You Wu</dc:creator>
<dc:creator>Helina Kassahun</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>OCEAN(a)-DOSE Trial Investigators</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial</dc:title>
<dc:identifier>pmid:39937508</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5433</dc:identifier>
</item>
<item>
<title>Intensive Blood Pressure Control in Older Adults-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937507/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5444. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937507/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937507</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5444>10.1001/jamacardio.2024.5444</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937507</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Xiaofan Guo</dc:creator>
<dc:creator>Guozhe Sun</dc:creator>
<dc:creator>Yingxian Sun</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Intensive Blood Pressure Control in Older Adults-Reply</dc:title>
<dc:identifier>pmid:39937507</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5444</dc:identifier>
</item>
<item>
<title>Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis-The Time Has Come</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5648. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937467</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5648>10.1001/jamacardio.2024.5648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937467</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Patricia A Pellikka</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis-The Time Has Come</dc:title>
<dc:identifier>pmid:39937467</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5648</dc:identifier>
</item>
<item>
<title>Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results suggest that the risk of SCD/MVA in phenotype-positive carriers of FLNCtv was high. A 5-variable predictive model derived from this cohort allows risk estimation and could support clinicians in the shared decision for prophylactic ICD implantation. External cohort validation is warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 12. doi: 10.1001/jamacardio.2024.5543. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Filamin C truncating variants (FLNCtv) are a rare cause of cardiomyopathy with heterogeneous phenotypic presentations. Despite a high incidence of life-threatening ventricular arrhythmias and sudden cardiac death (SCD), reliable risk predictors to stratify carriers of FLNCtv are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine factors predictive of SCD/major ventricular arrhythmias (MVA) in carriers of FLNCtv.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was an international, multicenter, retrospective cohort study conducted from February 2023 to June 2024. The Filamin C Registry Consortium included 19 referral centers for genetic cardiomyopathies worldwide. Participants included carriers of pathogenic or likely pathogenic FLNCtv. Phenotype negative was defined as the absence of any pathological findings detected by 12-lead electrocardiogram (ECG), Holter ECG monitoring, echocardiography, or cardiac magnetic resonance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Composite of SCD and MVA in carriers of FLNCtv.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of SCD and MVA, the last including aborted SCD, sustained ventricular tachycardia, and appropriate implantable cardioverter-defibrillator (ICD) interventions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 308 individuals (median [IQR] age, 45 [33-56] years; 160 male [52%]) with FLNCtv, 112 (36%) were probands, and 72 (23%) were phenotype negative. Median (IQR) left ventricular ejection fraction (LVEF) was 51% (38%-59%); 89 participants (34%) had LVEF less than 45%, and 50 (20%) had right ventricular dysfunction. During a median (IQR) follow-up of 34 (8-63) months, 57 individuals (19%) experienced SCD/MVA, with an annual incidence rate of 4 cases per 100 person-years (95% CI, 3-6). Incidence rates were higher in probands vs nonprobands and in phenotype-positive vs phenotype-negative individuals. A predictive model estimating SCD/MVA risk was derived from multivariable analysis, which included older age, male sex, previous syncope, nonsustained ventricular tachycardia, and LVEF with a time-dependent area under the curve (AUC) ranging between 0.76 (95% CI, 0.67-0.86) at 12 months and 0.78 (95% CI, 0.70-0.86) at 72 months. Notably, the association of LVEF with the SCD/MVA risk was not linear, showing significant lower risk for values of LVEF greater than 58%, and no increase for values less than 58%. Internal validation with bootstrapping confirmed good accuracy and calibration of the model. Results were consistent in subgroups analysis (ie, phenotype-positive carriers and phenotype-positive carriers without MVA at onset).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results suggest that the risk of SCD/MVA in phenotype-positive carriers of FLNCtv was high. A 5-variable predictive model derived from this cohort allows risk estimation and could support clinicians in the shared decision for prophylactic ICD implantation. External cohort validation is warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937464</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5543>10.1001/jamacardio.2024.5543</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937464</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Filamin C Registry Consortium</dc:creator>
<dc:creator>Marta Gigli</dc:creator>
<dc:creator>Davide Stolfo</dc:creator>
<dc:creator>Giulia Barbati</dc:creator>
<dc:creator>Sharon Graw</dc:creator>
<dc:creator>Suet Nee Chen</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Caterina Gregorio</dc:creator>
<dc:creator>Matteo Dal Ferro</dc:creator>
<dc:creator>Alessia Paldino</dc:creator>
<dc:creator>Maria Perotto</dc:creator>
<dc:creator>J Peter van Tintelen</dc:creator>
<dc:creator>Anneline S J M Te Riele</dc:creator>
<dc:creator>Annette F Baas</dc:creator>
<dc:creator>Arthur M Wilde</dc:creator>
<dc:creator>Ahmad S Amin</dc:creator>
<dc:creator>Arjan C Houweling</dc:creator>
<dc:creator>Perry Elliott</dc:creator>
<dc:creator>Douglas Cannie</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Stephan A C Schoonvelde</dc:creator>
<dc:creator>Sanjay Prasad</dc:creator>
<dc:creator>Paz Upasana Tayal</dc:creator>
<dc:creator>Momina Yazdani</dc:creator>
<dc:creator>Deborah Morris-Rosendahl</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Eva Cabrera-Romero</dc:creator>
<dc:creator>Barbara Bauce</dc:creator>
<dc:creator>Kalliopi Pilichou</dc:creator>
<dc:creator>Diane Fatkin</dc:creator>
<dc:creator>Renee Johnson</dc:creator>
<dc:creator>Daniel P Judge</dc:creator>
<dc:creator>Kimberly L Foil</dc:creator>
<dc:creator>Stephane Heymans</dc:creator>
<dc:creator>Job A J Verdonschot</dc:creator>
<dc:creator>Sophie L V M Stroeks</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Purohit Anisha</dc:creator>
<dc:creator>Matthew O'Neill</dc:creator>
<dc:creator>M Benjamin Shoemaker</dc:creator>
<dc:creator>Dan M Roden</dc:creator>
<dc:creator>Hugh Calkins</dc:creator>
<dc:creator>Cynthia A James</dc:creator>
<dc:creator>Brittney Murray</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Euan A Ashley</dc:creator>
<dc:creator>Chloe Reuter</dc:creator>
<dc:creator>Massimo Imazio</dc:creator>
<dc:creator>Marco Canepa</dc:creator>
<dc:creator>Pietro Ameri</dc:creator>
<dc:creator>Jiangping Song</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants</dc:title>
<dc:identifier>pmid:39937464</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5543</dc:identifier>
</item>
<item>
<title>Error in Abstract and Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 1;10(2):202. doi: 10.1001/jamacardio.2025.0009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937198</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0009>10.1001/jamacardio.2025.0009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937198</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Abstract and Results</dc:title>
<dc:identifier>pmid:39937198</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0009</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Feb 1;10(2):108. doi: 10.1001/jamacardio.2024.3409.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937197</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3409>10.1001/jamacardio.2024.3409</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937197</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39937197</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3409</dc:identifier>
</item>
<item>
<title>MYSTERY-HF - Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction - a Phase II Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39937049/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 12. doi: 10.1161/CIRCULATIONAHA.125.074085. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39937049/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39937049</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074085>10.1161/CIRCULATIONAHA.125.074085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39937049</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Simon Braumann</dc:creator>
<dc:creator>Sascha Macherey-Meyer</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:creator>Angelika Costard-Jäckle</dc:creator>
<dc:creator>Caroline Morbach</dc:creator>
<dc:creator>Bernhard Haring</dc:creator>
<dc:creator>Harald Lapp</dc:creator>
<dc:creator>Vincent Ten Cate</dc:creator>
<dc:creator>Alexander Gieswinkel</dc:creator>
<dc:creator>Jithmi Weliwitage</dc:creator>
<dc:creator>Martin Hellmich</dc:creator>
<dc:creator>Erik Michaëlsson</dc:creator>
<dc:creator>Karin Nelander</dc:creator>
<dc:creator>Nelli Ens-Jäger</dc:creator>
<dc:creator>Stephan Rosenkranz</dc:creator>
<dc:creator>Simon Gei C Df En</dc:creator>
<dc:creator>Norbert Frey</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Malin Aurell</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Stefan Frantz</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Philipp Wild</dc:creator>
<dc:creator>Stephan Baldus</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>MYSTERY-HF - Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction - a Phase II Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:39937049</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074085</dc:identifier>
</item>
<item>
<title>Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology EuroObservational Research Programme Peri-Partum Cardiomyopathy Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39936475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Maternal morbidity and mortality rates were lower than anticipated. Baseline LVEF &lt;50% was not associated with an increased frequency of adverse maternal outcomes, and no further decline in LVEF was observed in this group. In contrast, women with SSPs and a baseline LVEF ≥50% experienced a decline in LVEF, potentially attributable to reduced use of heart failure pharmacotherapy during pregnancy and the post-partum period. Therapeutic termination was performed in approximately a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 12:ehaf006. doi: 10.1093/eurheartj/ehaf006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The risk of heart failure progression or mortality in patients with peri-partum cardiomyopathy (PPCM) during subsequent pregnancies (SSPs) is a significant concern for patients, their families, and healthcare providers. However, there is limited contemporary, prospective data on SSP outcomes in PPCM patients from diverse ethnic and sociodemographic groups. This study aimed to assess maternal and neonatal outcomes in PPCM patients undergoing SSPs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a sub-study on PPCM and SSPs of the global European Society of Cardiology PPCM Registry that recruited patients from 2012 to 2023. Maternal and neonatal outcomes were reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 332 patients with PPCM, there were 98 SSPs among 73 women. Of these, 25 (26%) SSPs ended prematurely due to therapeutic termination (20/25), miscarriage (4/25), and stillbirth (1/25). The median follow-up from the end of the SSP was 198 days (inter-quartile range 160-240). Left ventricular ejection fraction (LVEF) was persistently reduced to &lt;50% prior to the SSP in 26% of patients, with only 6% having an LVEF &lt;40%. Patient characteristics were similar, irrespective of SSP baseline LVEF. Clinical worsening [composite of all-cause death, cardiovascular rehospitalization, or decline in LVEF ≥10% (percentage points) and to &lt;50%] occurred in 20% SSPs, with 2% all-cause maternal mortality. Signs/symptoms of heart failure and worsening of New York Heart Association class occurred in 26% and 22% of SSPs, respectively. At follow-up, the mean LVEF was 50% (±12%), and in 69% of SSPs, the LVEF was ≥50%. African women had similar outcome as the other ethnic groups. Pre-term delivery occurred in 24% of SSPs, 20% of babies were of low birth weight, and there was 3% all-cause neonatal mortality. Compared with women with SSP baseline LVEF &lt;50%, fewer women with LVEF ≥50% were on heart failure pharmacotherapies prior to the SSP, and in this group of women, there was a significant decline in LVEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Maternal morbidity and mortality rates were lower than anticipated. Baseline LVEF &lt;50% was not associated with an increased frequency of adverse maternal outcomes, and no further decline in LVEF was observed in this group. In contrast, women with SSPs and a baseline LVEF ≥50% experienced a decline in LVEF, potentially attributable to reduced use of heart failure pharmacotherapy during pregnancy and the post-partum period. Therapeutic termination was performed in approximately a fifth of cases. The findings suggest that reclassification of a SSP with persisting mild left ventricular impairment from modified World Health Organization (mWHO) Class IV (contraindicated) to mWHO III may be considered, while remaining under the care of an experienced medical team and with appropriate pharmacological management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39936475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39936475</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf006>10.1093/eurheartj/ehaf006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39936475</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Karen Sliwa</dc:creator>
<dc:creator>Alice Jackson</dc:creator>
<dc:creator>Charle Viljoen</dc:creator>
<dc:creator>Albertino Damasceno</dc:creator>
<dc:creator>Irina Mbanze</dc:creator>
<dc:creator>Hassan Al Farhan</dc:creator>
<dc:creator>Israa Fadhil Yaseen</dc:creator>
<dc:creator>Amam Mbakwem</dc:creator>
<dc:creator>Triwedya Indra Dewi</dc:creator>
<dc:creator>Zofia Dzielinska</dc:creator>
<dc:creator>Timur Abdullaev</dc:creator>
<dc:creator>Sorel Goland</dc:creator>
<dc:creator>Denise Hilfiker-Kleiner</dc:creator>
<dc:creator>Julia Hahnle</dc:creator>
<dc:creator>Carmen Basic</dc:creator>
<dc:creator>Alexandra Frogoudaki</dc:creator>
<dc:creator>Petar Seferovic</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology EuroObservational Research Programme Peri-Partum Cardiomyopathy Registry</dc:title>
<dc:identifier>pmid:39936475</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf006</dc:identifier>
</item>
<item>
<title>Mosaic loss of Y chromosome and mortality after coronary angiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39935193/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: LOY represents an important independent risk factor for cardiovascular mortality in male patients with coronary artery disease. Targeting LOY may represent a sex-specific personalized medicine approach.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 12:ehaf035. doi: 10.1093/eurheartj/ehaf035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Acquired somatic mutations emerged as important drivers of adverse cardiovascular disease outcomes. Recently, mosaic loss of Y chromosome (LOY) in haematopoietic cells was identified to induce diffuse cardiac fibrosis in male mice. The aim of the present study was to determine the association between LOY and cardiovascular mortality in patients undergoing coronary angiography.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: LOY was quantified in 1698 male participants of the LURIC study, who underwent coronary angiography, and its association with all-cause and cardiovascular mortality was determined. Furthermore, the interaction between LOY and inherited genetic susceptibility for cardiac fibrosis was assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The frequency of LOY steeply increased in male participants of LURIC at the age of 60 years. Loss of Y chromosome >; 17% was associated with significantly higher all-cause [hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.09-1.82] and cardiovascular mortality (HR 1.49, 95% CI 1.09-2.03), which was driven by a higher risk for fatal myocardial infarction (HR 2.65, 95% CI 1.46-4.81). Loss of Y chromosome >; 17% was associated with a profibrotic and proinflammatory plasma protein expression profile as characterized by higher plasma levels of osteoprotegerin, matrix metalloproteinase-12, growth differentiation factor 15, heparin-binding EGF-like growth factor, and resistin. Genetic predisposition for lower myocardial fibrosis attenuated the association between LOY and cardiovascular mortality. Genome-wide methylation analyses identified differential methylation in 298 genes including ACTB, RPS5, WDR1, CD151, and ARAP1. Single-cell RNA sequencing further confirmed differential gene expression of 37 of these genes in LOY in peripheral blood mononuclear cells comprising a set of fibrosis-regulating genes including RPS5. RPS5 silencing in macrophages induced a paracrine induction of collagen expression in cardiac fibroblasts documenting a functional role in vitro.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: LOY represents an important independent risk factor for cardiovascular mortality in male patients with coronary artery disease. Targeting LOY may represent a sex-specific personalized medicine approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39935193/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39935193</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf035>10.1093/eurheartj/ehaf035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39935193</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Michael Weyrich</dc:creator>
<dc:creator>Stephen Zewinger</dc:creator>
<dc:creator>Tamim Sarakpi</dc:creator>
<dc:creator>Tina Rasper</dc:creator>
<dc:creator>Marcus E Kleber</dc:creator>
<dc:creator>Sebastian Cremer</dc:creator>
<dc:creator>Lukas Zanders</dc:creator>
<dc:creator>Fenja Fleck</dc:creator>
<dc:creator>Agneta Siegbahn</dc:creator>
<dc:creator>Lars Wallentin</dc:creator>
<dc:creator>Wesley Tyler Abplanalp</dc:creator>
<dc:creator>Linda Nerbas</dc:creator>
<dc:creator>Sandra Fay</dc:creator>
<dc:creator>Aaron L Eberle</dc:creator>
<dc:creator>Stefanie Dimmeler</dc:creator>
<dc:creator>Winfried März</dc:creator>
<dc:creator>Thimoteus Speer</dc:creator>
<dc:creator>Andreas M Zeiher</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mosaic loss of Y chromosome and mortality after coronary angiography</dc:title>
<dc:identifier>pmid:39935193</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf035</dc:identifier>
</item>
<item>
<title>Suspected de novo heart failure in outpatient care: the REVOLUTION HF study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39935142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with suspected HF and elevated NT-proBNP had high mortality and morbidity in the weeks after presentation, and accrued substantial healthcare costs, highlighting an urgent need for prompt identification, evaluation, and treatment of HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 12:ehaf034. doi: 10.1093/eurheartj/ehaf034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Ambulatory patients presenting with signs or symptoms of heart failure (HF) should undergo natriuretic peptide testing. Rates of death, HF hospitalization, and healthcare costs were examined in patients thus identified with suspected de novo HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This population-based study (REVOLUTION HF) encompassing two large healthcare regions in Sweden examined patients who presented to outpatient care for the first time between 1 January 2015 and 31 December 2020, who had a recorded sign (peripheral oedema) or symptom (dyspnoea) of HF, and whose N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured >;300 ng/L within ±30 days of that sign or symptom. Characteristics, outcomes, healthcare patterns, and healthcare costs for these patients were followed for 1 year. Comparisons were made with matched controls without history of HF, its signs, its symptoms, or elevated NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 5942 patients (median age 78.7 years; 54% women) presented with suspected de novo HF. Within 1 year, 29% had received a HF diagnosis. Patients with suspected de novo HF had higher rates of all-cause death (11.7 vs. 6.5 events/100 person-years) and HF hospitalizations (12.5 vs. 2.2 events/100 person-years) than matched controls (n = 2048), with the highest event rates in the weeks after presentation. Rates were higher with higher NT-proBNP levels. Although some patients already used HF guideline-directed medical therapies for other indications, initiation of new medications was variable. Healthcare costs were higher in patients with suspected de novo HF than in matched controls, driven mostly by HF and chronic kidney disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with suspected HF and elevated NT-proBNP had high mortality and morbidity in the weeks after presentation, and accrued substantial healthcare costs, highlighting an urgent need for prompt identification, evaluation, and treatment of HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39935142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39935142</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf034>10.1093/eurheartj/ehaf034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39935142</guid>
<pubDate>Wed, 12 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Lisa Anderson</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Johan Bodegård</dc:creator>
<dc:creator>Katrina Mullin</dc:creator>
<dc:creator>Stefan Gustafsson</dc:creator>
<dc:creator>Giuseppe M C Rosano</dc:creator>
<dc:creator>Johan Sundström</dc:creator>
<dc:date>2025-02-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Suspected de novo heart failure in outpatient care: the REVOLUTION HF study</dc:title>
<dc:identifier>pmid:39935142</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf034</dc:identifier>
</item>
<item>
<title>Author Correction: Traction force microscopy of cardiomyocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39934356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 11. doi: 10.1038/s41569-025-01139-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39934356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39934356</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01139-w>10.1038/s41569-025-01139-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39934356</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Maia Lyall</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Author Correction: Traction force microscopy of cardiomyocytes</dc:title>
<dc:identifier>pmid:39934356</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01139-w</dc:identifier>
</item>
<item>
<title>Baseline characteristics and outcomes of rheumatic mitral valve disease: the EURObservational Research Programme Valvular Heart Disease II Survey</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39932741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Compliance with guideline recommendations for intervention is poor overall in patients with rheumatic valve disease. Concerted educational efforts are needed to improve the management of this vulnerable patient cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 11:ehaf050. doi: 10.1093/eurheartj/ehaf050. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Rheumatic heart disease is the commonest acquired cardiovascular disease worldwide. About 20 years have elapsed since the original Euro Heart Survey on valvular heart disease (VHD) was conducted with multiple changes in practice due to advances in treatment techniques. In this study, we aimed to analyse the management of patients with severe native valve disease or those with previous valvular intervention in comparison with existing European Society of Cardiology guidelines.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The European Society of Cardiology VHD II registry is an international, prospective, longitudinal multicentre, observational study, which was conducted in 222 centres. The registry included patients with severe native VHD or with previous valvular intervention. Follow-up was undertaken at 6 months at the investigating centre or by telephone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Amongst patients recruited in the European Society of Cardiology VHD II registry, 470 had severe rheumatic mitral valve disease and 332 had previous rheumatic mitral valve intervention. Amongst the patients with Class I recommendation for intervention, it was undertaken in only 70%. Adherence to guideline recommendations was more in patients with native VHD than in those with previous intervention. Total mortality was 1.5% in hospital and 3.5% at 6 months follow-up. Independent predictors of death at 6 months were age, chronic pulmonary disease, New York Heart Association Classes III and IV at presentation, liver dysfunction, and previous myocardial infarction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compliance with guideline recommendations for intervention is poor overall in patients with rheumatic valve disease. Concerted educational efforts are needed to improve the management of this vulnerable patient cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39932741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39932741</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf050>10.1093/eurheartj/ehaf050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39932741</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Magdy Abdelhamid</dc:creator>
<dc:creator>Amir M Abdel Meged</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Francisco E Calvo-Iglesias</dc:creator>
<dc:creator>Salma M Taha</dc:creator>
<dc:creator>Ghada A Kazamel</dc:creator>
<dc:creator>Mostafa M Abdrabou</dc:creator>
<dc:creator>Maiy H El Sayed</dc:creator>
<dc:creator>Minna M Kylmala</dc:creator>
<dc:creator>Olga B Irtyuga</dc:creator>
<dc:creator>Alec S Vahanian</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Cécile Laroche</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Baseline characteristics and outcomes of rheumatic mitral valve disease: the EURObservational Research Programme Valvular Heart Disease II Survey</dc:title>
<dc:identifier>pmid:39932741</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf050</dc:identifier>
</item>
<item>
<title>Scpep1 inhibition attenuates myocardial infarction-induced dysfunction by improving mitochondrial bioenergetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39932164/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Scpep1 deficiency mitigates MI by improving Pex3-mediated mitochondrial fission and subsequent cardiomyocyte apoptosis. Scpep1 constitutes a potential therapeutic target for attenuating MI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 11:ehaf032. doi: 10.1093/eurheartj/ehaf032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Myocardial infarction (MI) is an ischaemic cardiovascular disease associated with increased morbidity and mortality. Previous studies have suggested that serine carboxypeptidase 1 (Scpep1) is involved in vascular diseases; however, its role in cardiac diseases remains unclear. This study aims to explore the role of Scpep1 in regulating cardiac homeostasis during MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The impact of Scpep1 deficiency or cardiac-specific knock-down and Scpep1 overexpression on heart function was evaluated in mice with MI. Its downstream functional mediators of Scpep1 were elucidated using proteomic analysis and confirmed by employing loss- and gain-of-function strategies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Circulating and cardiac Scpep1 levels were up-regulated in mice with MI. Genetic ablation or cardiac-specific knock-down of Scpep1 alleviated MI-induced cardiac dysfunction and damage in mice. In contrast, cardiac-specific Scpep1 overexpression aggravated these adverse effects. Mechanistically, Scpep1 exacerbated MI-induced cardiac dysfunction and damage by impaired mitochondrial bioenergetics via binding to Pex3 to promote its degradation, ultimately contributing to mitochondrial fission and apoptosis. Moreover, the expressional profiles of Scpep1 in plasma samples and heart tissues of patients with MI or ischaemic cardiomyopathy were in line with those observed in the mouse models. In addition, pharmaceutical inhibition of Scpep1 notably improved MI-induced cardiac dysfunction and damage by improving mitochondrial fragmentation and bioenergetics post-MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Scpep1 deficiency mitigates MI by improving Pex3-mediated mitochondrial fission and subsequent cardiomyocyte apoptosis. Scpep1 constitutes a potential therapeutic target for attenuating MI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39932164/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39932164</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf032>10.1093/eurheartj/ehaf032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39932164</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Guilin Chen</dc:creator>
<dc:creator>Jing Gan</dc:creator>
<dc:creator>Fan Wu</dc:creator>
<dc:creator>Zengxian Zhou</dc:creator>
<dc:creator>Zikun Duan</dc:creator>
<dc:creator>Ke Zhang</dc:creator>
<dc:creator>Songxue Wang</dc:creator>
<dc:creator>Hua Jin</dc:creator>
<dc:creator>Yulin Li</dc:creator>
<dc:creator>Chi Zhang</dc:creator>
<dc:creator>Zhuofeng Lin</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Scpep1 inhibition attenuates myocardial infarction-induced dysfunction by improving mitochondrial bioenergetics</dc:title>
<dc:identifier>pmid:39932164</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf032</dc:identifier>
</item>
<item>
<title>Takotsubo is an acute myocardial ischaemic syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39932154/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 11:ehaf020. doi: 10.1093/eurheartj/ehaf020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39932154/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39932154</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf020>10.1093/eurheartj/ehaf020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39932154</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Robert Sykes</dc:creator>
<dc:creator>Daniel T Y Ang</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Takotsubo is an acute myocardial ischaemic syndrome</dc:title>
<dc:identifier>pmid:39932154</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf020</dc:identifier>
</item>
<item>
<title>SMC Abca1 and Abcg1 Deficiency Enhances Urinary Bladder Distension but Not Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39931819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We uncover a new role of SMC cholesterol efflux pathways in suppressing α(1)-AR-mediated vasoconstriction and bladder SMC transdifferentiation, decreasing urinary bladder distension. Our data may provide a mechanistic link for the association between urinary bladder distension and diabetes in humans, particularly because diabetes is associated with decreased cholesterol efflux. SMC-Abca1/Abcg1 deficiency did not affect atherosclerotic lesion size or plaque composition, presumably...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 11. doi: 10.1161/CIRCRESAHA.124.325103. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Smooth muscle cells (SMCs) regulate blood flow distribution via vasoconstriction mediated by α-ARs (α-adrenergic receptors). Plasma membrane cholesterol accumulation affects α<sub>1</sub>-AR signaling and promotes loss of SMC contractile markers in vitro. ABCA1 and ABCG1 (ATP-binding cassette transporter A1 and G1) mediate cholesterol efflux to HDL (high-density lipoprotein). ABCA1/ABCG1 show high expression in medial and low expression in intimal SMCs of atherosclerotic plaques. The role of ABCA1 and ABCG1 in SMC-mediated vasoconstriction and atherogenesis remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We generated mice with SMC-specific <i>Abca1/Abcg1</i> deficiency on the low-density lipoprotein receptor-deficient (<i>Ldlr</i><sup><i>-</i></sup><sup><i>/</i></sup><sup><i>-</i></sup>) background by crossbreeding <i>Abca1</i><sup><i>fl/fl</i></sup><i>Abcg1</i><sup><i>fl/fl</i></sup><i>Ldlr</i><sup><i>-/-</i></sup> mice with <i>Myh11Cre</i><sup><i>ERT2</i></sup> transgenic mice. To induce SMC cholesterol accumulation and atherogenesis, we fed <i>Myh11Cre</i><sup><i>ERT2</i></sup><i>Abca1</i><sup><i>fl/fl</i></sup><i>Abcg1</i><sup><i>fl/fl</i></sup><i>Ldlr</i><sup><i>-/-</i></sup>, <i>Myh11Cre</i><sup><i>ERT2</i></sup><i>Abca1</i><sup><i>fl/fl</i></sup><i>Ldlr</i><sup><i>-/-</i></sup>, <i>Myh11Cre</i><sup><i>ERT2</i></sup><i>Abcg1</i><sup><i>fl/fl</i></sup><i>Ldlr</i><sup><i>-/-</i></sup>, and <i>Myh11Cre</i><sup><i>ERT2</i></sup><i>Ldlr</i><sup><i>-/-</i></sup> mice Western-type diet for 16 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Combined <i>SMC-Abca1/Abcg1</i> deficiency increased vasoconstriction in aortic rings induced by the α<sub>1</sub>-AR agonist phenylephrine. Unexpectedly, <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency induced urinary bladder distension by >;20-fold. This was reversed by the α<sub>1</sub>-AR antagonist tamsulosin, indicating its dependence on bladder neck SMC constriction. Moreover, <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency decreased contractile markers and increased macrophage and fibroblast markers in bladder SMCs, indicating SMC transdifferentiation. This was accompanied by free cholesterol accumulation and increased endoplasmic reticulum stress. <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency did not induce thoracic aorta SMC transdifferentiation, presumably due to increased cholesteryl ester accumulation and no endoplasmic reticulum stress in thoracic aorta SMCs. Surprisingly, <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency did not affect atherosclerotic lesion size or composition in the aortic root or brachiocephalic artery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We uncover a new role of SMC cholesterol efflux pathways in suppressing α<sub>1</sub>-AR-mediated vasoconstriction and bladder SMC transdifferentiation, decreasing urinary bladder distension. Our data may provide a mechanistic link for the association between urinary bladder distension and diabetes in humans, particularly because diabetes is associated with decreased cholesterol efflux. <i>SMC</i>-<i>Abca1/Abcg1</i> deficiency did not affect atherosclerotic lesion size or plaque composition, presumably due to low expression of <i>Abca1/Abcg1</i> in intimal SMCs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39931819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39931819</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325103>10.1161/CIRCRESAHA.124.325103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39931819</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Benedek Halmos</dc:creator>
<dc:creator>Anouk M La Rose</dc:creator>
<dc:creator>Daisey Methorst</dc:creator>
<dc:creator>Anouk G Groenen</dc:creator>
<dc:creator>Dalibor Nakládal</dc:creator>
<dc:creator>Venetia Bazioti</dc:creator>
<dc:creator>Mirjam H Koster</dc:creator>
<dc:creator>Niels J Kloosterhuis</dc:creator>
<dc:creator>Azuwerus van Buiten</dc:creator>
<dc:creator>Elisabeth M Schouten</dc:creator>
<dc:creator>Nicolette C A Huijkman</dc:creator>
<dc:creator>Miriam Langelaar-Makkinje</dc:creator>
<dc:creator>Laura Bongiovanni</dc:creator>
<dc:creator>Simon M De Neck</dc:creator>
<dc:creator>Alain de Bruin</dc:creator>
<dc:creator>Hendrik Buikema</dc:creator>
<dc:creator>Leo E Deelman</dc:creator>
<dc:creator>Marius C van den Heuvel</dc:creator>
<dc:creator>Folkert Kuipers</dc:creator>
<dc:creator>Igle Jan de Jong</dc:creator>
<dc:creator>Judith C Sluimer</dc:creator>
<dc:creator>Helle F Jørgensen</dc:creator>
<dc:creator>Robert H Henning</dc:creator>
<dc:creator>Marit Westerterp</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>SMC Abca1 and Abcg1 Deficiency Enhances Urinary Bladder Distension but Not Atherosclerosis</dc:title>
<dc:identifier>pmid:39931819</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325103</dc:identifier>
</item>
<item>
<title>Risk of Incident Atrial Fibrillation in Women With a History of Hypertensive Disorders of Pregnancy: A Population-Based Retrospective Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39931813/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Women exposed to HDP in their first delivery have a significantly increased cause-specific hazard ratios of incident AFib compared to their unexposed counterparts, with higher rates observed in subjects exposed to more severe de novo HDP diagnoses as well as chronic hypertension in pregnancy. These findings underscore the need to consider HDP history in risk calculation/stratification for arrhythmic and nonarrhythmic cardiovascular diseases, improve surveillance of traditional and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11. doi: 10.1161/CIRCULATIONAHA.124.072418. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality and are associated with acute cardiac events in the peripartum period, as well as cardiovascular disease later in life. Despite the robust association between hypertension and atrial fibrillation (AFib), comparatively little is known about HDP and its subtypes as sex-specific risk factors for AFib.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A population-based retrospective cohort study was conducted, including 771 521 nulliparous women discharged for obstetrical delivery of their first live or stillborn singleton infant between 2002 and 2017 in Ontario, Canada. Data were obtained from record-level, coded, and linked population-based administrative databases housed at ICES. Using competing risks Cox proportional hazards regression, we estimated crude and multivariable-adjusted cause-specific hazard ratios and 95% CIs for associations between history of any HDP (and its 6 subtypes), and AFib before death, as well as all-cause mortality without a previous AFib diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Approximately 8% of women were diagnosed with HDP during the 16-year exposure accrual period. The total person-time of follow-up was 7 380 304 person-years, during which there were 2483 (0.3%) incident AFib diagnoses and 2951 (0.4%) deaths. History of any HDP was associated with an increased cause-specific hazard ratios of incident AFib and death without a previous AFib diagnosis (adjusted cause-specific hazard ratios, 1.45 [95% CI, 1.28-1.64] and 1.31 [95% CI, 1.16-1.47], respectively). These associations were observed in relatively young women (median time to event, 7 years postpartum). Associations suggestive of a dose-response relationship were observed, with more severe HDP subtypes and prepregnancy chronic hypertension associated with a 1.5 to 2.2 times higher cause-specific rate of AFib, and a 1.4 to 2.1 times higher cause-specific rate of death compared with no hypertension in pregnancy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Women exposed to HDP in their first delivery have a significantly increased cause-specific hazard ratios of incident AFib compared to their unexposed counterparts, with higher rates observed in subjects exposed to more severe de novo HDP diagnoses as well as chronic hypertension in pregnancy. These findings underscore the need to consider HDP history in risk calculation/stratification for arrhythmic and nonarrhythmic cardiovascular diseases, improve surveillance of traditional and female-specific cardiovascular disease risk factors, and develop targeted prevention strategies to reduce the occurrence and burden of HDP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39931813/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39931813</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072418>10.1161/CIRCULATIONAHA.124.072418</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39931813</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Amy Johnston</dc:creator>
<dc:creator>William Petrcich</dc:creator>
<dc:creator>Graeme N Smith</dc:creator>
<dc:creator>Deshayne B Fell</dc:creator>
<dc:creator>Peter Tanuseputro</dc:creator>
<dc:creator>Thais Coutinho</dc:creator>
<dc:creator>Jodi D Edwards</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk of Incident Atrial Fibrillation in Women With a History of Hypertensive Disorders of Pregnancy: A Population-Based Retrospective Cohort Study</dc:title>
<dc:identifier>pmid:39931813</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072418</dc:identifier>
</item>
<item>
<title>Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39931812/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings bring forth the CXCR3-CXCL9/10 axis as an attractive therapeutic target for ICI myocarditis treatment, and more broadly as a druggable pathway in cardiac inflammation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 11. doi: 10.1161/CIRCRESAHA.124.325652. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used a genetic mouse model of PD1 deletion (<i>MRL/Pdcd1</i><sup><i>-/-</i></sup>) along with a novel drug-treated ICI myocarditis mouse model to recapitulate the disease phenotype. We performed single-cell RNA-sequencing, single-cell T-cell receptor sequencing, and cellular indexing of transcriptomes and epitopes on immune cells isolated from <i>MRL</i> and <i>MRL/Pdcd1</i><sup><i>-/-</i></sup> mice at serial time points. We assessed the impact of macrophage deletion in <i>MRL/Pdcd1</i><sup><i>-/-</i></sup> mice, then inhibited CXCR3 (C-X-C motif chemokine receptor 3) in ICI-treated mice to assess the therapeutic effect on myocarditis phenotype. Furthermore, we delineated the functional and mechanistic effects of CXCR3 blockade on T-cell and macrophage interactions. We then correlated the results in human single-cell multiomics data from blood and heart biopsy data from patients with ICI myocarditis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Single-cell multiomics demonstrated expansion of CXCL (C-X-C motif chemokine ligand) 9/10+CCR2+ macrophages and CXCR3hi (C-X-C motif chemokine receptor 3 high-expressing) CD8+ (cluster of differentiation) effector T lymphocytes in the hearts of <i>MRL/Pdcd1</i><sup><i>-/-</i></sup> mice correlating with onset of myocarditis development. Both depletion of CXCL9/10+CCR2+ (C-C motif chemokine receptor) macrophages and CXCR3 blockade, respectively, led to decreased CXCR3hi CD8+ T-cell infiltration into the heart and significantly improved survival. Transwell migration assays demonstrated that the selective blockade of CXCR3 and its ligand, CXCL10, reduced CXCR3+CD8+ T-cell migration toward macrophages, implicating this interaction in T-cell cardiotropism toward cardiac macrophages. Furthermore, cardiomyocyte apoptosis was induced by CXCR3hi CD8+ T cells. Cardiac biopsies from patients with confirmed ICI myocarditis demonstrated infiltrating CXCR3+ T cells and CXCL9+/CXCL10+ macrophages. Both mouse cardiac immune cells and patient peripheral blood immune cells revealed expanded TCR s (T-cell receptors) correlating with CXCR3hi CD8+ T cells in ICI myocarditis samples.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings bring forth the CXCR3-CXCL9/10 axis as an attractive therapeutic target for ICI myocarditis treatment, and more broadly as a druggable pathway in cardiac inflammation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39931812/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39931812</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325652>10.1161/CIRCRESAHA.124.325652</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39931812</guid>
<pubDate>Tue, 11 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yuhsin Vivian Huang</dc:creator>
<dc:creator>Yin Sun</dc:creator>
<dc:creator>Harrison Chou</dc:creator>
<dc:creator>Noah Wagner</dc:creator>
<dc:creator>Maria Rosaria Vitale</dc:creator>
<dc:creator>Abraham L Bayer</dc:creator>
<dc:creator>Bruce Xu</dc:creator>
<dc:creator>Daniel Lee</dc:creator>
<dc:creator>Zachary Lin</dc:creator>
<dc:creator>Corynn Branche</dc:creator>
<dc:creator>Sarah Waliany</dc:creator>
<dc:creator>Joel W Neal</dc:creator>
<dc:creator>Heather A Wakelee</dc:creator>
<dc:creator>Ronald M Witteles</dc:creator>
<dc:creator>Patricia K Nguyen</dc:creator>
<dc:creator>Edward E Graves</dc:creator>
<dc:creator>Gerald J Berry</dc:creator>
<dc:creator>Pilar Alcaide</dc:creator>
<dc:creator>Sean M Wu</dc:creator>
<dc:creator>Han Zhu</dc:creator>
<dc:date>2025-02-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis</dc:title>
<dc:identifier>pmid:39931812</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325652</dc:identifier>
</item>
<item>
<title>Remuscularizing the failing heart in primates</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39930039/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 10. doi: 10.1038/s41569-025-01136-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39930039/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39930039</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01136-z>10.1038/s41569-025-01136-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39930039</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Remuscularizing the failing heart in primates</dc:title>
<dc:identifier>pmid:39930039</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01136-z</dc:identifier>
</item>
<item>
<title>Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39929237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250212195220&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 11:ehaf031. doi: 10.1093/eurheartj/ehaf031. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39929237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250212195220&v=2.18.0.post9+e462414">39929237</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf031>10.1093/eurheartj/ehaf031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39929237</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)</dc:title>
<dc:identifier>pmid:39929237</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf031</dc:identifier>
</item>





























</channel>
</rss>